SynthesisEndocrine2017
Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review.
Synthesis in Endocrine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Mesenchymal stem cell-derived extracellular vesicles therapy for primary ovarian insufficiency: a systematic review and meta-analysis of pre-clinical studies.Journal of ovarian research · 2024Pooled it
- Cardiovascular Events Among Women with Premature Ovarian Insufficiency: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2023Pooled it
- Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency.The Cochrane database of systematic reviews · 2022Pooled it
- Pooled it
- Effect of Transdermal Estrogen Therapy on Bone and Neurobehavioral Health in Youth with Premature Ovarian Insufficiency: A Case-Control Study.Journal of pediatric and adolescent gynecology · 2025Article
- Local estradiol deposition in a rat rotator cuff repair model: proof of concept.JSES international · 2025Article
- Metabolic Changes in Patients with Premature Ovarian Insufficiency: Adipose Tissue Focus-A Narrative Review.Metabolites · 2025Review
- Bone health in women with premature ovarian insufficiency/early menopause: a 23-year longitudinal analysis.Human reproduction (Oxford, England) · 2024Article
- Primary ovarian insufficiency: update on clinical and genetic findings.Frontiers in endocrinology · 2024Review
- Review
- Clinical analysis of human umbilical cord mesenchymal stem cell allotransplantation in patients with premature ovarian insufficiency.Cell proliferation · 2020Article
- Severe Phenotype of APECED (APS1) Increases Risk for Structural Bone Alterations.Frontiers in endocrinology · 2020Article
- Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up.Hormone research in paediatrics · 2019Review
- Effects of Estrogen in Gender-dependent Fetal Programming of Adult Cardiovascular Dysfunction.Current vascular pharmacology · 2019Review
- Estrogen-inducedChinese medical journal · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
Abstract
purposeSex hormones play a role in bone density, cardiovascular health, and wellbeing throughout reproductive lifespan. Women with primary ovarian insufficiency (POI) have lower estrogen levels requiring hormone therapy (HT) to manage symptoms and to protect against adverse long-term health outcomes. Yet, the effectiveness of HT in preventing adverse outcomes has not been systematically assessed. We summarize the evidence regarding effects of HT on bone and cardiovascular health in women with POI.
methodsA comprehensive search of the electronic databases MEDLINE, EMBASE, and Scopus was conducted by a medical reference librarian from database inception to January 2016. Randomized trials and observational cohort studies with an estrogen-based HT intervention in women with POI under the age of 40 were included. Reviewers worked independently and in duplicate to assess eligibility and risk of bias, and extract data of interest from each study.
resultsThe search identified 1670 articles; 12 met inclusion criteria. Four randomized clinical trials and eight cohort studies at high risk of bias enrolled 806 women with POI. The most common HT formulations were transdermal estradiol and oral conjugated equine estrogen combined with medroxyprogesterone acetate. Bone mineral density was the most frequent outcome, with three out of eight studies showing HT associated increase benefits. Only one study reported effects on fractures or vasomotor symptoms and none on cardiovascular mortality. Results regarding lipid profiles were inconsistent.
conclusionsEvidence supporting bone and cardiovascular benefits of HT in women with POI is limited by high risk of bias, reliance on surrogate outcomes, and heterogeneity of trials regarding the formulation, dose, route of administration, and regimen of HT. Further research addressing patient important outcomes such as fractures, stroke, and cardiovascular mortality are crucial to optimize benefits of this therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.